Abnormal platelet aggregation is NOT a defining feature of coexisting SLE and APS
The answer is d) abnormal platelet aggregation. When SLE and antiphospholipid syndrome coexist, the diagnostic hallmarks include positive anticardiolipin antibodies, positive lupus anticoagulant, and false-positive syphilis tests—but abnormal platelet aggregation is not a standard diagnostic criterion or consistent finding in this overlap syndrome 1, 2.
Core Laboratory Features of SLE-APS Overlap
The laboratory diagnosis of APS (whether primary or secondary to SLE) centers on three cornerstone antibodies 1:
- Lupus anticoagulant (LA) - detected through clotting assays
- Anticardiolipin antibodies (aCL) - measured by ELISA
- Anti-β2-glycoprotein I antibodies (aβ2GPI) - measured by ELISA
These antibodies must be persistently positive on at least two occasions 12 weeks apart for APS classification 1, 2.
Why Each Answer Choice Matters
Positive Anticardiolipin Antibodies (Option a) - PRESENT
Anticardiolipin antibodies are one of the three essential laboratory criteria for APS diagnosis 1. In SLE patients with secondary APS, aCL prevalence ranges from 78% to high levels, particularly when measured at moderate-to-high titers (≥40 Units) 3. This is definitively present in SLE-APS overlap.
Positive Lupus Anticoagulant (Option b) - PRESENT
Lupus anticoagulant is another core diagnostic antibody for APS 1. Studies show LA prevalence of 12-42% in SLE patients with secondary APS 3. Notably, patients with both LA and high-titer aCL face significantly higher risk for thrombotic complications—up to 48.6% developed arterial thrombosis in one cohort 4. This is definitively present in SLE-APS overlap.
False-Positive Syphilis Test (Option c) - PRESENT
False-positive syphilis serology (particularly VDRL/RPR tests) occurs because anticardiolipin antibodies cross-react with the cardiolipin antigen used in these treponemal screening tests. This has been a recognized phenomenon in both SLE and APS since their early descriptions 2. This is present in SLE-APS overlap.
Abnormal Platelet Aggregation (Option d) - NOT A DIAGNOSTIC CRITERION
While one older study 4 demonstrated that the combination of aCL and LA IgG antibodies could enhance platelet activation in vitro when combined with ADP stimulation, this finding:
- Is not part of the classification criteria for APS 1, 2
- Is not routinely tested in clinical practice for APS diagnosis
- Represents a potential pathophysiologic mechanism rather than a diagnostic feature
- Was demonstrated only under specific experimental conditions with combined antibodies and platelet agonists
Critical Distinction: Pathophysiology vs. Diagnostic Criteria
The 2023 ACR/EULAR classification criteria and current ISTH guidance 1 make clear that APS diagnosis relies on the three antibody tests mentioned above—not platelet function studies. While antiphospholipid antibodies may affect platelet activation as part of their prothrombotic mechanism 4, abnormal platelet aggregation testing is neither required nor routinely performed for diagnosing the coexistence of SLE and APS.
Clinical Pitfall to Avoid
Do not confuse thrombocytopenia (low platelet count), which is common in SLE-APS overlap and was present in 70.6% of patients with arterial thrombosis in one series 4, with abnormal platelet aggregation testing. Thrombocytopenia is a clinical manifestation, while platelet aggregation studies are specialized laboratory tests not part of standard APS workup.